Nuformix (LON:NFX) Shares Down 7.7% – Time to Sell?

Nuformix plc (LON:NFX)’s stock price traded down 7.7% during trading on Thursday . The company traded as low as GBX 0.23 and last traded at GBX 0.23. 1,843,170 shares changed hands during trading, a decline of 95% from the average session volume of 33,943,625 shares. The stock had previously closed at GBX 0.25.

Nuformix Trading Down 1.2%

The firm has a market cap of £5.11 million, a P/E ratio of -6.16 and a beta of 1.22. The business has a 50 day moving average of GBX 0.26 and a two-hundred day moving average of GBX 0.23.

Nuformix (LON:NFX) last posted its earnings results on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.